Generic Name: dolutegravir + rilpivirine
Abbreviation: DTG + RPV
Other Market Name: N/A
Drug Class: Single-Tablet Regimens
Company: ViiV Healthcare and Janssen Therapeutics
Approval Status: Experimental
Generic Version Available: No
Experimental Code: N/A
DTG + RPV has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.
DTG + RPV is an experimental HIV medication. It contains an approved integrase inhibitor and an approved non-nucleoside reverse transcriptase inhibitor. It is currently in Phase III clinical trials.
DTG+ RPV is a single-tablet regimen containing two currently approved HIV medications (dolutegravir and rilpivirine). It is being developed as two-drug “maintenance therapy” for people living with HIV. In clinical trials, study participants must first decrease their viral loads to undetectable levels using a three-drug treatment regimen before switching to the two-drug single-tablet regimen.
Adult Dose: One tablet once a day. Each tablet contains 50mg dolutegravir + 25mg rilpivirine.
Pediatric Dose: N/A
Dosing Info: This is a complete one-pill, once-daily drug regimen.
Last Revised: September 5, 2017